GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Vimian Group AB (OSTO:VIMIAN) » Definitions » EV-to-EBITDA

Vimian Group AB (OSTO:VIMIAN) EV-to-EBITDA : 30.16 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vimian Group AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vimian Group AB's enterprise value is kr23,905 Mil. Vimian Group AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was kr793 Mil. Therefore, Vimian Group AB's EV-to-EBITDA for today is 30.16.

The historical rank and industry rank for Vimian Group AB's EV-to-EBITDA or its related term are showing as below:

OSTO:VIMIAN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 18.2   Med: 30.95   Max: 87.54
Current: 30.64

During the past 7 years, the highest EV-to-EBITDA of Vimian Group AB was 87.54. The lowest was 18.20. And the median was 30.95.

OSTO:VIMIAN's EV-to-EBITDA is ranked worse than
81.58% of 114 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.35 vs OSTO:VIMIAN: 30.64

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-12), Vimian Group AB's stock price is kr40.95. Vimian Group AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.061. Therefore, Vimian Group AB's PE Ratio (TTM) for today is 671.31.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Vimian Group AB EV-to-EBITDA Historical Data

The historical data trend for Vimian Group AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vimian Group AB EV-to-EBITDA Chart

Vimian Group AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - 86.67 32.41 21.01

Vimian Group AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.75 21.01 23.96 24.46 33.83

Competitive Comparison of Vimian Group AB's EV-to-EBITDA

For the Diagnostics & Research subindustry, Vimian Group AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vimian Group AB's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vimian Group AB's EV-to-EBITDA falls into.



Vimian Group AB EV-to-EBITDA Calculation

Vimian Group AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=23905.211/792.649
=30.16

Vimian Group AB's current Enterprise Value is kr23,905 Mil.
Vimian Group AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr793 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vimian Group AB  (OSTO:VIMIAN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Vimian Group AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=40.95/0.061
=671.31

Vimian Group AB's share price for today is kr40.95.
Vimian Group AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.061.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Vimian Group AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vimian Group AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vimian Group AB Business Description

Traded in Other Exchanges
Address
Riddargatan 19, Stockholm, SWE, SE-11457
Vimian Group AB specializes in the areas of animal health such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription and non-prescription treatments for preventive care, and treatment of chronic conditions for companion animals, with a strong position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.

Vimian Group AB Headlines

No Headlines